AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26499146 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only FOLFOX regimen
Number of subjects: 103
Study 23341353 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants receiving additional information about the screening programme
Number of subjects: 2059
Study 23341353 — intervention group
Group type: COMPARATOR
Intervention: Non-participants receiving additional information
Number of subjects: 2059
Study 21325456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery women
Number of subjects: 98
Study 21325456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery women in summer
Number of subjects: 98
Study 21325456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery women in winter
Number of subjects: 98
Study 19207894 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with internal sinus lift (ISL) without graft material
Number of subjects: 36
Study 19207894 — intervention group
Group type: COMPARATOR
Intervention: Control group (native posterior maxilla implants)
Number of subjects: 36
Study 19207894 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with ISL
Number of subjects: 36
Study 17559913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (5, 10, 20, or 40 mg/m² intravenously)
Number of subjects: 49
Study 17559913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15040783 — intervention group
Group type: EXPERIMENTAL
Intervention: PMD3117 (Ang I vaccine)
Number of subjects: 27
Study 15040783 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide (Alhydrogel)
Number of subjects: 27
Study 11828273 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with estradiol valerate and cyproterone acetate (Pausene(R))
Number of subjects: 100
Study 11828273 — intervention group
Group type: COMPARATOR
Intervention: Cacit Vitamin D30(R) (Control Group)
Number of subjects: 100
Study 9658688 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ teicoplanin treatment
Number of subjects: 12
Study 9658688 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical amikacin therapy switched to teicoplanin
Number of subjects: 12
Study 7709042 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 48
Study 7709042 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta IFN
Number of subjects: 48
Study 7709042 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin + Beta IFN
Number of subjects: 48
Study 7709042 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study 2649462 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO; 11 g/m2)
Number of subjects: 626
Study 2649462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study 322546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 2.5 mg
Number of subjects: 140
Study 322546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 5 mg
Number of subjects: 140
Study 322546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 10 mg
Number of subjects: 140
Study 322546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 20 mg
Number of subjects: 140
Study 30407270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 344
Study 30407270 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344
Study 30407270 — intervention group
Group type: COMPARATOR
Intervention: Internet-based exercise program
Number of subjects: 344
Study 27814282 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 51
Study 27814282 — intervention group
Group type: COMPARATOR
Intervention: Sham remote ischemic preconditioning (sRIPC)
Number of subjects: 51
Study 25948027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic Group (IV infusion of ephedrine 37.5 mg/h)
Number of subjects: 36
Study 25948027 — intervention group
Group type: COMPARATOR
Intervention: Non‐Pharmacologic Group (15° left lateral tilt)
Number of subjects: 36
Study 22954665 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400mg, orally, twice daily) plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Number of subjects: 220
Study 22954665 — intervention group
Group type: COMPARATOR
Intervention: placebo plus paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
Number of subjects: 220
Study 21320086 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideRite® nasal tracheal tube
Number of subjects: 110
Study 21320086 — intervention group
Group type: COMPARATOR
Intervention: pre‐rotated RAE™ nasal tracheal tube
Number of subjects: 110
Study 19186715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using acupoint group I (BL 15, BL 18, BL 20, BL 23) and acupoint group II (CV 4, CV 3, SP 6, KI 3, LR 3)
Number of subjects: 111
Study 19186715 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment with Sailete tablets, 20 mg each tablet, one tablet each night
Number of subjects: 111
Study 16984495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d. for 7 days
Number of subjects: 21
Study 16984495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14986209 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-on-yellow (B/Y) perimetry
Number of subjects: 80
Study 14986209 — intervention group
Group type: COMPARATOR
Intervention: White-on-white (W/W) perimetry
Number of subjects: 80
Study 14986209 — intervention group
Group type: COMPARATOR
Intervention: Normal values from Twinfield Perimeter
Number of subjects: 80
Study 14986209 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 80
Study 11131626 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with forearm crutches
Number of subjects: 19
Study 9102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement group (n = 14, mean calcium intake 1988 +/- 90 mg/day)
Number of subjects: 84
Study 9102058 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21, mean calcium intake 952 +/- 109 mg/day)
Number of subjects: 84
Study 9102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant group (n = 49, mean calcium intake 981 +/- 75 mg/day)
Number of subjects: 84
Study 9102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 84
Study 7689519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 115
Study 7689519 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 115
Study 3736025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate forms of the Peabody Picture Vocabulary Test (PPVT)
Number of subjects: 154
Study 31533717 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient web portal usage
Number of subjects: 7749
Study 31533717 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowing DXA test results
Number of subjects: 7749
Study 31533717 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of web portal users
Number of subjects: 7749
Study 31533717 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient awareness of test results
Number of subjects: 7749
Study 29133605 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 3642
Study 26059390 — intervention group
Group type: EXPERIMENTAL
Intervention: Paro (companion robot)
Number of subjects: 37
Study 24844389 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐PTFE membranes
Number of subjects: 15
Study 24844389 — intervention group
Group type: COMPARATOR
Intervention: Control (no membranes)
Number of subjects: 15
Study 22549115 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus pioglitazone (15 mg every 12 h)
Number of subjects: 40
Study 22549115 — intervention group
Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 40
Study 20338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted retroperitoneoscopic donor nephrectomy
Number of subjects: 0
Study 20338030 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic donor nephrectomy
Number of subjects: 0
Study 18848141 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg azimilide
Number of subjects: 633
Study 18848141 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg azimilide
Number of subjects: 633
Study 18848141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 15088872 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal probes (4 different types)
Number of subjects: 8
Study 15088872 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy (SEM) examination of probe tips
Number of subjects: 8
Study 11755322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 30
Study 11755322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg followed by an infusion of 6-10 mg/kg.hr(-1))
Number of subjects: 30
Study 11755322 — intervention group
Group type: COMPARATOR
Intervention: Control (air/oxygen/isoflurane anesthesia)
Number of subjects: 30
Study 10193349 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 19
Study 10193349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8000128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2)
Number of subjects: 32
Study 8000128 — intervention group
Group type: COMPARATOR
Intervention: Iodinated contrast material
Number of subjects: 32
Study 3178440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization (group A)
Number of subjects: 20
Study 3178440 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization (group B)
Number of subjects: 20
Study 1092585 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 15
Study 1092585 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 15
Study 1092585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol 25 mg
Number of subjects: 15
Study 1092585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28195970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest (COOL)
Number of subjects: 10
Study 28195970 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 28786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (improving community participation in vector control)
Number of subjects: 24
Study 28786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (ultra-low volume (ULV) spraying)
Number of subjects: 24
Study 28786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (A and B)
Number of subjects: 24
Study 28786919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 28786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 24
Study 28786919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 24
Study 26135593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1500 mg
Number of subjects: 100
Study 26135593 — intervention group
Group type: COMPARATOR
Intervention: Oral levetiracetam 1500 mg
Number of subjects: 100
Study 26135593 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous levetiracetam 1500 mg
Number of subjects: 100
Study 26135593 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100
Study 23839771 — intervention group
Group type: EXPERIMENTAL
Intervention: CSMD1 risk 'A' allele
Number of subjects: 150
Study 21447413 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary vitamin K intake
Number of subjects: 365
Study 21447413 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake
Number of subjects: 365
Study 21447413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study 18419721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV intra-operatively with parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Number of subjects: 160
Study 18419721 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g IV during surgery and 1 g PO for 7 days
Number of subjects: 160
Study 18419721 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV during surgery and valdecoxib 40 mg PO for 7 days
Number of subjects: 160
Study 18419721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV intra-operatively with paracetamol 1 g IV during surgery and 1 g PO for 7 days
Number of subjects: 160
Study 16981923 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA pacing >50% of the time (pacing group, n=46)
Number of subjects: 76
Study 16981923 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing <50% of the time (sensing group, n=30)
Number of subjects: 76
Study 14513808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of finasteride
Number of subjects: 20
Study 10837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT)
Number of subjects: 32
Study 9265936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 2.3% end-tidal concentration
Number of subjects: 30
Study 8314483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units interferon (IFN) alfa‐2b three times a week for three months
Number of subjects: 0
Study 8314483 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study 8314483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units interferon (IFN) alfa‐2b
Number of subjects: 0
Study 3514204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 3 g/day
Number of subjects: 19
Study 3514204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3514204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG)
Number of subjects: 19
Study 28464434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (G1)
Number of subjects: 123
Study 28464434 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with PFMT (G2)
Number of subjects: 123
Study 28464434 — intervention group
Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 123
Study 27990435 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120
Study 27990435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120
Study 27990435 — intervention group
Group type: COMPARATOR
Intervention: Axillary brachial plexus block with 20 mL ropivacaine 0.75%
Number of subjects: 120
Study 24781895 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (210 mL, 19.5-mmol nitrate)
Number of subjects: 8
Study 24781895 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-free BR placebo (PL)
Number of subjects: 8
Study 22562554 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily)
Number of subjects: 420
Study 22562554 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily or 5 mg twice daily)
Number of subjects: 420
Study 22562554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22562554 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25-50 mg once daily)
Number of subjects: 420
Study 20685688 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of signs of congestion (elevated jugular venous pressure, orthopnoea, ascites, or oedema)
Number of subjects: 2647
Study 20685688 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of congestion
Number of subjects: 2647
Study 18818161 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacylglycerol (DAG)
Number of subjects: 5
Study 18818161 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol (TAG)
Number of subjects: 5
Study 16182674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10, 20, and 30 mg
Number of subjects: 580
Study 16182674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS XR; Adderall XR(R)) 10 to 30 mg/day
Number of subjects: 580
Study 16182674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 12766930 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg mane
Number of subjects: 12
Study 12766930 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine 15mg/30mg nocte (comparator)
Number of subjects: 12
Study 12766930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15mg mane/15mg b.i.d. (verum)
Number of subjects: 12
Study 12766930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10690136 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine
Number of subjects: 22
Study 10690136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 10690136 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine for low cardiac output
Number of subjects: 22
Study 8932548 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin (400 mg twice a day for 5 doses)
Number of subjects: 9
Study 8932548 — intervention group
Group type: COMPARATOR
Intervention: procainamide (1 g oral single dose)
Number of subjects: 9
Study 1867179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg twice daily for 5 days every 3 months
Number of subjects: 64
Study 1867179 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64
Study 1867179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin treatment
Number of subjects: 64
Study 6732679 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 40
Study 6732679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31984508 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment for 8 weeks, five sessions
Number of subjects: 10
Study 31984508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31984508 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 10
Study 30378323 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate dressing
Number of subjects: 40
Study 30378323 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze
Number of subjects: 40
Study 27019511 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective BRAF inhibitor (vemurafenib)
Number of subjects: 24
Study 27019511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 24
Study 27019511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (dabrafenib/trametinib)
Number of subjects: 24
Study 27019511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (alone or in combination)
Number of subjects: 24
Study 27019511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 24
Study 24120464 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with prednisone
Number of subjects: 0
Study 22370330 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Meaning‐Centered Psychotherapy (IMCP)
Number of subjects: 120
Study 22370330 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Massage (TM)
Number of subjects: 120
Study 20398352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole + Risedronate (A+R)
Number of subjects: 213
Study 20398352 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole only (A)
Number of subjects: 213
Study 18627623 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 23
Study 18627623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17357850 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with loud white-noise event (80 db) at fixed 120 s intervals during a 5-min EGM gambling session.
Number of subjects: 69
Study 17357850 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no white noise).
Number of subjects: 69
Study 14694352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg b.i.d. alprazolam
Number of subjects: 68
Study 14694352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg b.i.d. alprazolam
Number of subjects: 68
Study 14694352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg b.i.d. lorazepam
Number of subjects: 68
Study 14694352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg b.i.d. lorazepam
Number of subjects: 68
Study 14694352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 1)
Number of subjects: 69
Study 10969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 2)
Number of subjects: 69
Study 10969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml (group 3)
Number of subjects: 69
Study 10969298 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation at target plasma concentrations from 0.5 to 4.0 microgram/ml
Number of subjects: 69
Study 9085317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiloride (10 mg of amiloride 1‐mg/ml solution)
Number of subjects: 19
Study 9085317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amiloride (4.5 ml of 1‐mg/ml solution in 12% saline)
Number of subjects: 19
Study 9085317 — intervention group
Group type: COMPARATOR
Intervention: Comparison of oral vs inhalation administration
Number of subjects: 19
Study 8412202 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 4‐HPR daily for 52 weeks
Number of subjects: 137
Study 8412202 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 137